Use of human small leucine zipper protein in osteogenesis procedure

• US 9,962,425 B2
• Filed: 04/30/2014
• Issued: 05/08/2018
• Est. Priority Date: 04/30/2013
• Status: Active Grant

• Current Assignee: Korea University Research and Business Foundation (Korea University)
• Original Assignee: Korea University Research and Business Foundation (Korea University)
• Inventors: Ko, Je Sang, Kim, Jeong-Han
• Primary Examiner(s): Steele, Amber D
• Application Number:
  US14/888,340
• Publication Number:
  US 20160067308A1
• Time in Patent Office: 1,469 Days
• Field of Search: None
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: G01N 2333/47 Assays involving proteins of known structure or function as defined in the subgroups
• CPC Class Codes: G01N 33/502 for testing non-proliferative effects
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPARγ2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.

Claims

1. A method for promoting differentiation of a mesenchymal stem cell into an osteoblast in vitro, comprising

culturing the mesenchymal stem cell in a differentiation medium comprising a human small leucine-zipper protein.

2. The method of claim 1, wherein the human small leucine-zipper protein comprises the amino acid sequence of SEQ ID NO:

1.

3. The method of claim 1, wherein the differentiation medium comprises a Dulbecco'"'"'s modified Eagle'"'"'s medium (DMEM) supplemented with ascorbic acid, β

-glycerophosphate, and serum.

4. The method of claim 1, wherein the differentiation medium further comprises at least one differentiation-inducing factor selected from the group consisting of a ciliary neurotrophic factor (CNTF), bone morphogenetic proteins (BMPs), a transforming growth factor (TGFα

), and a neuregulin-1 (Nrg1)/glial growth factor-2 (GGF2).